Valuation: Sarepta Therapeutics, Inc.

Market Cap 2.16B 1.87B 1.76B 1.6B 3B 206B 3.03B 21.05B 8.11B 105B 8.11B 7.93B 333B P/E 2026 *
6.71x
P/E 2027 * 37.9x
Enterprise Value 1.88B 1.62B 1.53B 1.39B 2.61B 179B 2.63B 18.29B 7.04B 91.22B 7.05B 6.89B 290B EV / Sales 2026 *
1.02x
EV / Sales 2027 * 1.04x
Free-Float
94.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.30%
1 week-7.02%
Current month-0.52%
1 month+13.57%
3 months+36.64%
6 months+27.56%
Current year-2.79%
1 week 19.51
Extreme 19.51
23.22
1 month 17.72
Extreme 17.724
23.62
Current year 14.68
Extreme 14.68
24.68
1 year 14.68
Extreme 14.68
25.32
3 years 10.42
Extreme 10.415
173.25
5 years 10.42
Extreme 10.415
173.25
10 years 10.42
Extreme 10.415
181.83
Manager TitleAgeSince
Chief Executive Officer 60 2026-07-27
Director of Finance/CFO 47 2025-07-15
Director of Finance/CFO 50 2020-12-13
Director TitleAgeSince
Chairman 73 2015-04-15
Director/Board Member 87 2010-05-31
Director/Board Member 67 2015-06-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Tax

Chief Financial Officer

-13,272 0.0126%
9/4/26 Tax

General Counsel

-22,025 0.0209%
9/4/26 Tax

Chairperson

-24,799 0.0235%
Change 5-day change 1-year change 3-year change Capi.($)
+2.30%-7.02%+20.30%-82.42% 2.16B
-4.83%-11.05%-55.10%-66.77% 1.41B
0.00%-0.63%-21.97%-4.99% 358M
-0.90%-3.51%-49.43% - 52.97M
Average -0.86%-3.98%-26.55%-51.39% 994.23M
Weighted average by Cap. -0.47%-7.13%-11.08%-69.74%

Financials

2026 *2027 *
Net sales 1.84B 1.59B 1.5B 1.36B 2.55B 176B 2.57B 17.91B 6.9B 89.33B 6.9B 6.75B 284B 1.38B 1.2B 1.13B 1.02B 1.92B 132B 1.93B 13.46B 5.18B 67.14B 5.19B 5.07B 213B
Net income 366M 317M 299M 271M 508M 34.94B 512M 3.56B 1.37B 17.78B 1.37B 1.34B 56.43B 39.41M 34.13M 32.2M 29.2M 54.78M 3.77B 55.2M 384M 148M 1.92B 148M 145M 6.08B
Net Debt -284M -246M -232M -210M -395M -27.13B -398M -2.77B -1.07B -13.81B -1.07B -1.04B -43.82B -724M -627M -591M -536M -1.01B -69.14B -1.01B -7.05B -2.72B -35.19B -2.72B -2.66B -112B
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
835
Date Price Change Volume
26-09-14 US$20.92 +2.30% 2,152,600
26-09-11 US$20.45 -0.34% 1,810,736
26-09-10 US$20.52 -6.81% 2,204,294
26-09-09 US$22.02 +5.16% 4,167,542
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
20.92USD
Average target price
22.26USD
Spread / Average Target
+6.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRPT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!